Pall purchases BioSMB technology from Tarpon Biosystems

Published: 1-Apr-2015
Manufacturing Finance

Expands downstream continuous processing capabilities


Pall, a filtration, separation and purification specialist, has acquired the BioSMB technology platform from Tarpon Biosystems. These chromatographic systems enable single-use, multicolumn chromatography for process development and are suitable for multiproduct and single-use facilities.

BioSMB technology is fully scalable from process development to large-scale GMP production. The disposable flow path features a proprietary integrated valve cassette and services up to 16 columns or devices.

Ken Frank, Senior Vice President at Pall Life Sciences, said: 'We are pleased to add this cutting-edge technology to our growing portfolio of products and services. It extends our process intensification and continuous processing capabilities to support customers as they adopt continuous downstream processing.'

He added that the BioSMB technology incorporates disposable components to enable flexible, multiproduct biomanufacturing while reducing costs.

This latest addition expands Pall’s portfolio in continuous processing technology at both the process development and GMP scales of operation, while complementing existing Allegro single-use products and systems.

  • Companies:
  • Pall Life Sciences
See more

You may also like

Drug Delivery

Cytiva completes integration with Pall Corporation

Read more
This new Cytiva supports customers in solving major biotechnology challenges, playing a critical role in advancing and accelerating therapeutics

Trending Articles

  1. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  2. CDMO GBI Biomanufacturing expands US drug product services with aseptic fill/finish capabilities Its Florida site will now be able to support biopharma clients from clinical trials to commercialisation with a dual manual/automated fill/finish approach
  3. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  4. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  5. Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Drug Delivery

Cytiva completes integration with Pall Corporation

This new Cytiva supports customers in solving major biotechnology challenges, playing a critical role in advancing and accelerating therapeutics
Manufacturing

Delivering an effective COVID-19 vaccine at record speed

COVID-19 is not the first pandemic that we’ve faced but, based on its ease and speed of transmission, it’s certainly one of the most threatening that we’ve experienced in recent history. Many countries have suffered long lockdowns; and, although we’re slowly seeing a loosening of restrictions in some areas, a safe and effective vaccine will be a crucial element in most national “exit strategies” for COVID-19
Manufacturing

Biopharmaceuticals: Integrated automation for downstream processing

John Welsh, Senior Manager at Pall Biotech, on why the biopharma industry must develop its own technology, the challenges to overcome, and efforts underway to offer seamless continuous bioproduction throughout a process
Manufacturing

Lessons for the biopharma sector on automation, analytics and embracing Industry 4.0

The pharmaceutical industry is undergoing a rapid transformation, with biopharmaceuticals now representing the market’s fastest-growing subsector and increasing treatment options for patients, reports Loe Cameron, Director of Analytics and Controls, Pall Corporation
Manufacturing

Pall Corporation wins supply contract with Servier

The filtration specialist will supply exclusive tech and services to Servier's new biomanufacturing site in France
Distribution

Pall and ARTeSYN Biosolutions to accelerate the industrialisation of single-use technology

Customers will benefit from the flexibility, agility and reliability required for their bioprocessing journey, says Pall
Manufacturing

Pall and Broadley-James to deliver next generation single-use sensor technologies to the life science market

Pall, a global leader in filtration, separation and purification, has partnered with Broadley-James Corporation, a renowned sensor technology provider, to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors
Subscribe now